Letolizumab
Letolizumab
Letolizumab (pronounced leh-toh-lih-zoo-mab) is a monoclonal antibody designed for the treatment of autoimmune diseases and transplant rejection.
Etymology
The name "Letolizumab" is derived from the International Nonproprietary Names (INN), where 'le' stands for human, 'to' for immunomodulating, 'li' for immunoglobulin, 'zu' for humanized, and 'mab' for monoclonal antibody.
Usage
Letolizumab is used in the treatment of various autoimmune diseases such as rheumatoid arthritis, psoriasis, and Crohn's disease. It is also used to prevent transplant rejection in patients who have undergone organ transplant.
Mechanism of Action
Letolizumab works by binding to the CD6 protein on the surface of T cells, a type of white blood cell. This inhibits the activation and proliferation of T cells, thereby reducing the immune response that causes autoimmune diseases and transplant rejection.
Related Terms
- Monoclonal antibody
- Autoimmune diseases
- Transplant rejection
- Rheumatoid arthritis
- Psoriasis
- Crohn's disease
- Organ transplant
- CD6
- White blood cell
External links
- Medical encyclopedia article on Letolizumab
- Wikipedia's article - Letolizumab
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski